TY - CPAPER
AU - Paterson, Clare
AU - Hinterberg, Michael A.
AU - Morrow, Andrew J.
AU - Sykes, Robert
AU - Mangion, Kenneth
AU - Welsh, Paul
AU - McConnachie, Alex
AU - Sattar, Naveed
AU - Berry, Colin
AU - Williams, Stephen A.
PY - 2022
DA - October
TI - Utility of a Proteomic Surrogate for Cardiovascular Outcomes to Predict and Monitor COVID-19 Induced Myocarditis
VL - 146
IS - S1
DO - https://doi.org/10.1161/circ.146.suppl_1.12132
AB - Introduction: Poorer cardiovascular (CV) health is a risk factor for adverse outcomes from COVID-19, and a proportion of COVID-19 survivors exhibit CV dysfunction including myocardial inflammation after initial recovery. However, biomarker-driven predictors of CV outcomes in COVID-19 are lacking. We recently demonstrated that a proteomic surrogate of CV outcomes (MI, stroke, hospitalization for heart failure, or death within 4 years) is highly predictive of acute COVID-19 severity. The current study expands on this to determine if a proteomic CV risk test associates with myocarditis likelihood in COVID-19 survivors. Methods: The SomaScan® platform was used for plasma proteomic phenotyping in CISCO-19 trial participants (n=154, mean age 55y, 43% Female) at hospital discharge following COVID-19, and at follow-up within 6-months later when comprehensive CV assessment including cardiac MRI for myocarditis adjudication was performed. N=20 (13%) were classified as very likely to have myocarditis at follow-up. We used linear mixed models to test proteomic CV scores at both visits against myocarditis likelihood across COVID-19 recovery and compared the predictive performance of the CV risk score to discriminate myocarditis likelihood to performance of Troponin I (TnI) and NT-proBNP. Results: A 36% relative CV risk reduction was observed during COVID-19 recovery. CV risk scores were significantly higher among those very likely myocarditis positive at follow up (p &lt; 0.05 for effects) (Figure 1). Additionally, the performance of the CV risk test in classifying myocarditis likelihood at follow-up was superior to that of TnI or NT-proBNP (AUC=0.64 vs 0.52 and 0.51, respectively). Conclusions: A proteomic predictor of CV risk has potential to support cardiac screening and monitoring CV health across the course of COVID-19 recovery, with diagnostic specificity superior to that of specific single cardiac biomarkers. Future studies with this approach seem warranted.
PB - American Heart Association
UR - https://eprints.gla.ac.uk/321233/
KW - Coronavirus (COVID-19)
ER